The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
AR101 Oral Immunotherapy for Peanut Allergy
Open accessAbstract
BACKGROUND: Peanut allergy, for which there are no approved treatment options, affects patients who are at risk for unpredictable and occasionally life-threatening allergic reactions. METHODS: In a phase 3 trial, we screened participants 4 to 55 years of age with peanut allergy for allergic dose-limiting symptoms at a challenge dose of 100 mg or less of peanut protein (approximately one third of a peanut kernel) in a double-blind, placebo-controlled food challenge. Participants with an allergic response were randomly assigned, in a 3:1 ratio, to receive AR101 (a peanut-derived investigational biologic oral immunotherapy drug) or placebo in an escalating-dose program. Participants who completed the regimen (i.e., received 300 mg per day of the maintenance regimen for approximately 24 weeks) underwent a double-blind, placebo-controlled food challenge at trial exit. The primary efficacy end point was the proportion of participants 4 to 17 years of age who could ingest a challenge dose of 600 mg or more, without dose-limiting symptoms. RESULTS: Of the 551 participants who received AR101 or placebo, 496 were 4 to 17 years of age; of these, 250 of 372 participants (67.2%) who received active treatment, as compared with 5 of 124 participants (4.0%) who received placebo, were able to ingest a dose of 600 mg or more of peanut protein, without dose-limiting symptoms, at the exit food challenge (difference, 63.2 percentage points; 95% confidence interval, 53.0 to 73.3; P<0.001). During the exit food challenge, the maximum severity of symptoms was moderate in 25% of the participants in the active-drug group and 59% of those in the placebo group and severe in 5% and 11%, respectively. Adverse events during the intervention period affected more than 95% of the participants 4 to 17 years of age. A total of 34.7% of the participants in the active-drug group had mild events, as compared with 50.0% of those in the placebo group; 59.7% and 44.4% of the participants, respectively, had events that were graded as moderate, and 4.3% and 0.8%, respectively, had events that were graded as severe. Efficacy was not shown in the participants 18 years of age or older. CONCLUSIONS: In this phase 3 trial of oral immunotherapy in children and adolescents who were highly allergic to peanut, treatment with AR101 resulted in higher doses of peanut protein that could be ingested without dose-limiting symptoms and in lower symptom severity during peanut exposure at the exit food challenge than placebo. (Funded by Aimmune Therapeutics; PALISADE ClinicalTrials.gov number, NCT02635776 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boyce, J. A., Assa'ad, A., Burks, A. W., Jones, S. M., Sampson, H. A., Wood, R. A., Plaut, M., Cooper, S. F., Fenton, M. J., Arshad, S. H., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.10.008 · Cited by 2,350
Sampson, H. A., Muñoz-Furlong, A., Campbell, R. L., Adkinson, N. F., Bock, S. A., Branum, A., Brown, S. G. A., Camargo, C. A., Cydulka, R., Galli, S. J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.12.1303 · Cited by 2,313
Fatalities due to anaphylactic reactions to foods
Bock, S. A., Muñoz-Furlong, A., & Sampson, H. A. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.112031 · Cited by 1,566
The prevalence, severity, and distribution of childhood food allergy in the United States
Gupta, R. S., Springston, E. E., Warrier, M. R., Smith, B., Kumar, R., Pongracic, J., & Holl, J. L. (2011) · PEDIATRICS · doi:10.1542/peds.2011-0204 · Cited by 1,417
EAACI Food Allergy and Anaphylaxis Guidelines: Diagnosis and Management of Food Allergy
Muraro, A., Werfel, T., Hoffmann-Sommergruber, K., Roberts, G., Beyer, K., Bindslev-Jensen, C., Cardona, V., Dubois, A., duToit, G., Eigenmann, P., et al. (2014) · Allergy · doi:10.1111/all.12429 · Cited by 1,116
US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up
Sicherer, S. H., Muñoz-Furlong, A., Godbold, J. H., & Sampson, H. A. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.03.029 · Cited by 932
Food allergy: A practice parameter update—2014
Sampson, H. A., Aceves, S., Bock, S. A., James, J., Jones, S., Lang, D., Nadeau, K., Nowak-Wegrzyn, A., Oppenheimer, J., Perry, T. T., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.05.013 · Cited by 845
Sampson, H. A., Gerth van Wijk, R., Bindslev-Jensen, C., Sicherer, S., Teuber, S. S., Burks, A. W., Dubois, A. E. J., Beyer, K., Eigenmann, P. A., Spergel, J. M., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.10.017 · Cited by 744
Oral Immunotherapy for Treatment of Egg Allergy in Children
Burks, A. W., Jones, S. M., Wood, R. A., Fleischer, D. M., Sicherer, S. H., Lindblad, R. W., Stablein, D., Henning, A. K., Vickery, B. P., Liu, A. H., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200435 · Cited by 700
Food allergy: immune mechanisms, diagnosis and immunotherapy
Yu, W., Freeland, D. M. H., & Nadeau, K. C. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.111 · Cited by 659
Farrington, C. P., & Manning, G. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091208 · Cited by 657
The natural history of peanut allergy
Skolnick, H. S., Conover-Walker, M. K., Koerner, C. B., Sampson, H. A., Burks, W., & Wood, R. A. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.112129 · Cited by 611
EAACI Guidelines on allergen immunotherapy: IgE‐mediated food allergy
Pajno, G. B., Fernandez‐Rivas, M., Arasi, S., Roberts, G., Akdis, C. A., Alvaro‐Lozano, M., Beyer, K., Bindslev‐Jensen, C., Burks, W., Ebisawa, M., et al. (2018) · Allergy · doi:10.1111/all.13319 · Cited by 566
Varshney, P., Jones, S. M., Scurlock, A. M., Perry, T. T., Kemper, A., Steele, P., Hiegel, A., Kamilaris, J., Carlisle, S., Yue, X., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.12.1111 · Cited by 557
Sicherer, S. H., Muñoz-Furlong, A., Burks, A. W., & Sampson, H. A. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70224-1 · Cited by 474
Anagnostou, K., Islam, S., King, Y., Foley, L., Pasea, L., Bond, S., Palmer, C., Deighton, J., Ewan, P., & Clark, A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62301-6 · Cited by 422
Allergen immunotherapy for IgE‐mediated food allergy: a systematic review and meta‐analysis
Nurmatov, U., Dhami, S., Arasi, S., Pajno, G. B., Fernandez‐Rivas, M., Muraro, A., Roberts, G., Akdis, C., Alvaro‐Lozano, M., Beyer, K., et al. (2017) · Allergy · doi:10.1111/all.13124 · Cited by 419
Oral peanut immunotherapy in children with peanut anaphylaxis
Blumchen, K., Ulbricht, H., Staden, U., Dobberstein, K., Beschorner, J., de Oliveira, L. C. L., Shreffler, W. G., Sampson, H. A., Niggemann, B., Wahn, U., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.04.030 · Cited by 384
Lucendo, A. J., Arias, Á., & Tenias, J. M. (2014) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2014.08.004 · Cited by 368
Vander Leek, T. K., Liu, A. H., Stefanski, K., Blacker, B., & Bock, S. A. (2000) · The Journal of Pediatrics · doi:10.1067/mpd.2000.109376 · Cited by 260
The natural progression of peanut allergy: Resolution and the possibility of recurrence
Fleischer, D. M., Conover-Walker, M. K., Christie, L., Burks, A. W., & Wood, R. A. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.1517 · Cited by 239
Optimally weighted, fixed sequence and gatekeeper multiple testing procedures
Westfall, P. H., & Krishen, A. (2001) · Journal of Statistical Planning and Inference · doi:10.1016/s0378-3758(01)00077-5 · Cited by 239
Allergen reference doses for precautionary labeling (VITAL 2.0): Clinical implications
Allen, K. J., Remington, B. C., Baumert, J. L., Crevel, R. W. R., Houben, G. F., Brooke-Taylor, S., Kruizinga, A. G., & Taylor, S. L. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.06.042 · Cited by 215
Food allergen immunotherapy: Current status and prospects for the future
Wood, R. A. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.01.001 · Cited by 208
Bird, J. A., Spergel, J. M., Jones, S. M., Rachid, R., Assa'ad, A. H., Wang, J., Leonard, S. A., Laubach, S. S., Kim, E. H., Vickery, B. P., et al. (2018) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2017.09.016 · Cited by 200
Virkud, Y. V., Burks, A. W., Steele, P. H., Edwards, L. J., Berglund, J. P., Jones, S. M., Scurlock, A. M., Perry, T. T., Pesek, R. D., & Vickery, B. P. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.030 · Cited by 135
Grimshaw, K. E. C., Bryant, T. N., Oliver, E. M., Martin, J. K., Maskell, J., Kemp, T., Mills, E. N. C., Foote, K. D., Margetts, B., Beyer, K., et al. (2015) · Clinical and Translational Allergy · doi:10.1186/s13601-016-0089-8 · Cited by 116
Food allergy: nuts and tree nuts
Crespo, J. F., James, J. M., Fernández, C. R., & Rodríguez, J. (2006) · British Journal Of Nutrition · doi:10.1017/bjn20061869 · Cited by 92
Improving the safety of oral immunotherapy for food allergy
Vázquez‐Ortiz, M., & Turner, P. (2015) · Pediatric Allergy and Immunology · doi:10.1111/pai.12510 · Cited by 87
Cited by
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Chu, D. K., Wood, R. A., French, S., Fiocchi, A., Jordana, M., Waserman, S., Brożek, J. L., & Schünemann, H. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30420-9 · Cited by 448
Allergen immunotherapy: past, present and future
Durham, S. R., & Shamji, M. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00786-1 · Cited by 413
Jones, S. M., Kim, E. H., Nadeau, K. C., Nowak-Wegrzyn, A., Wood, R. A., Sampson, H. A., Scurlock, A. M., Chinthrajah, S., Wang, J., Pesek, R. D., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02390-4 · Cited by 345
Omalizumab for the Treatment of Multiple Food Allergies
Wood, R. A., Togias, A., Sicherer, S. H., Shreffler, W. G., Kim, E. H., Jones, S. M., Leung, D. Y. M., Vickery, B. P., Bird, J. A., Spergel, J. M., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312382 · Cited by 337
Metadata
- Authors
- The PALISADE Group of Clinical Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-22
- Volume
- 379
- Issue
- 21
- Pages
- 1991-2001
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2947397217
- Cited by
- 765
- References
- 29
- FWCI
- 49.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.